Vorasidenib
Vorasidenib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target isocitrate dehydrogenase [NADP], mitochondrial and isocitrate dehydrogenase [NADP] cytoplasmic.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioma | D005910 | EFO_0000520 | 2 | — | 1 | — | 1 | 4 |
Indications Phases 2
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | — | — | 1 | 1 | ||
| Neoplasms | D009369 | C80 | — | — | — | — | 1 | 1 | |
| Germ cell and embryonal neoplasms | D009373 | — | — | — | — | 1 | 1 | ||
| Neoplasms by histologic type | D009370 | — | — | — | — | 1 | 1 | ||
| Glandular and epithelial neoplasms | D009375 | — | — | — | — | 1 | 1 | ||
| Nerve tissue neoplasms | D009380 | — | — | — | — | 1 | 1 | ||
| Neuroepithelial neoplasms | D018302 | — | — | — | — | 1 | 1 | ||
| Neuroectodermal tumors | D017599 | — | — | — | — | 1 | 1 | ||
| Disease attributes | D020969 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | VORASIDENIB |
| INN | vorasidenib |
| Description | Vorasidenib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target isocitrate dehydrogenase [NADP], mitochondrial and isocitrate dehydrogenase [NADP] cytoplasmic. |
| Classification | Small molecule |
| Drug class | mutated isocitrate dehydrogenase (IDH) inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F |
Identifiers
| PDB | — |
| CAS-ID | 1644545-52-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4279047 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 789Q85GA8P (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
IDH2
IDH2
IDH1
IDH1
Organism
Homo sapiens
Gene name
IDH2
Gene synonyms
NCBI Gene ID
Protein name
isocitrate dehydrogenase [NADP], mitochondrial
Protein synonyms
ICD-M, IDP, isocitrate dehydrogenase (NADP(+)) 2, mitochondrial, isocitrate dehydrogenase 2 (NADP+), mitochondrial, NADP(+)-specific ICDH, Oxalosuccinate decarboxylase
Uniprot ID
Mouse ortholog
Idh2 (269951)
isocitrate dehydrogenase [NADP], mitochondrial (Q9EQK1)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 157 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more